TP53 and B-cell chronic lymphocytic leukemia: Interestingly, ibrutinib completely overcomes the negative prognostic impact of unmutated IGHV genes, and since its mode of action is independent of TP53, it also smoothens the detrimental impact of TP53 disruption in CLL cells [37] (Table 2).